Vor Biopharma Inc.(VOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VOR Vor Biopharma Inc.

Market Closed 09-25 16:00:00 EDT

18.52

+0.08

+0.43%

盘后18.52

+0.000.00%

19:47 EDT

High18.71	Low17.95	Vol792.83K
Open18.62	D1 Closing18.44	Amplitude4.12%
Mkt Cap1.10B	Tradable Cap689.56M	Total Shares59.16M
T/O14.58M	T/O Rate2.13%	Tradable Shares37.23M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VOR","market":"US","secType":"STK","nameCN":"Vor Biopharma Inc.","latestPrice":18.52,"timestamp":1790366400000,"preClose":18.44,"halted":0,"volume":792829,"hourTrading":{"tag":"盘后","latestPrice":18.52,"preClose":18.52,"latestTime":"19:47 EDT","volume":15126,"amount":280132.67,"timestamp":1790380057546,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.004338394793926155,"floatShares":37233400,"shares":59162294,"eps":11.528,"marketStatus":"Market Closed","change":0.08,"latestTime":"09-25 16:00:00 EDT","open":18.62,"high":18.71,"low":17.95,"amount":14579162.815593999,"amplitude":0.041215,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":11.528,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790582400000},"marketStatusCode":7,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":18.44,"preHourTrading":{"tag":"盘前","latestPrice":18.6927,"preClose":18.44,"latestTime":"09:26 EDT","volume":134,"amount":2457.8326899999997,"timestamp":1790342800976,"change":0.2527,"changeRate":0.013704,"amplitude":0.035938},"postHourTrading":{"tag":"盘后","latestPrice":18.52,"preClose":18.52,"latestTime":"19:47 EDT","volume":15126,"amount":280132.67,"timestamp":1790380057546,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.3079621142768003,"impliedVol":1.5225,"impliedVolPercentile":0.9149},"requestUrl":"/m/hq/s/VOR/tweets","defaultTab":"tweets","newsList":[{"id":"2666123562","title":"Citi Keeps Their Buy Rating on Vor Biopharma (VOR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666123562","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666123562?lang=en_us&edition=fundamental","pubTime":"2026-09-10 18:16","pubTimestamp":1789035401,"startTime":"0","endTime":"0","summary":"Citi analyst Geoff Meacham maintained a Buy rating on Vor Biopharma yesterday and set a price target of $50.00. The company’s shares closed yesterd...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-keeps-their-buy-rating-on-vor-biopharma-vor-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-keeps-their-buy-rating-on-vor-biopharma-vor-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665278903","title":"Vor Bio completes enrollment in UPSTREAM MG trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665278903","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665278903?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:10","pubTimestamp":1788865835,"startTime":"0","endTime":"0","summary":"Vor Bio (VOR) announced the completion of enrollment in UPSTREAM MG, its global Phase 3 registrational trial evaluating telitacicept for the treatm...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vor-bio-completes-enrollment-in-upstream-mg-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vor-bio-completes-enrollment-in-upstream-mg-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322904","title":"Vor Bio Completes Enrollment in Phase 3 Upstream MG Trial for Telitacicept in Generalized Myasthenia Gravis","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322904","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322904?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:03","pubTimestamp":1788865388,"startTime":"0","endTime":"0","summary":"Vor Bio completes enrollment in Phase 3 UPSTREAM MG trial for telitacicept in generalized myasthenia gravisVor Bio completed enrollment in its global Phase 3 UPSTREAM MG trial of telitacicept in gener","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL2P1gph:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BKPKM429.USD","SG9999014039.USD","LU0314104364.USD","IE00BN0W2W23.USD","IE00BQXX3F31.USD","LU2095319765.USD","LU2210149790.SGD","IE00BQXX3C00.GBP","SG9999014021.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4139","BCDF","BK4585","SG9999014005.SGD","SG9999014013.SGD","VOR","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","NDAQ","BK4112","IE00BN0W2V16.EUR","IE00BQXX3D17.EUR","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665225483","title":"Vor Completes Enrollment of Global Phase 3 Upstream Mg Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis","url":"https://stock-news.laohu8.com/highlight/detail?id=2665225483","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665225483?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:00","pubTimestamp":1788865200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUAZKHMF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665225133","title":"Vor Biopharma - Upstream Mg 24-Week Primary Endpoint Results Expected in First Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2665225133","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665225133?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:00","pubTimestamp":1788865200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUAZKHMF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665351781","title":"Vor Bio files automatic mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2665351781","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665351781?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:40","pubTimestamp":1788554409,"startTime":"0","endTime":"0","summary":"16:36 EDT Vor Bio (VOR) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breakin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vor-bio-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vor-bio-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665513993","title":"Vor Biopharma Inc. - Files for Mixed Shelf; Size not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2665513993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665513993?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:31","pubTimestamp":1788553918,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nFWN44W0XE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665406359","title":"Vor Bio Grants 83,600 Stock Options, 17,900 RSUs to New Hires Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2665406359","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665406359?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:05","pubTimestamp":1788552322,"startTime":"0","endTime":"0","summary":"Vor Bio grants 83,600 stock options, 17,900 RSUs to new hires under inducement planVor Biopharma granted equity awards on Sept. 1, 2026 to six new employees.Stock options cover 83,600 shares, priced a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL6jZ9LV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014013.SGD","SG9999014039.USD","IE00BQXX3D17.EUR","SG9999014021.USD","IE00BKPKM429.USD","LU2095319765.USD","IE00BQXX3C00.GBP","IE00BGHQF748.EUR","BK4585","BK4139","LU2210150020.SGD","BK4112","BCDF","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","BK4588","IE00B64PRP62.GBP","IE00BN0W2W23.USD","VOR","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014005.SGD","LU0314104364.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663700958","title":"Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2663700958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663700958?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:50","pubTimestamp":1788184220,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vor Biopharma (VOR), Definium Therapeutics (DFTX) an...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vor-biopharma-vor-definium-therapeutics-dftx-and-ideaya-biosciences-idya-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vor-biopharma-vor-definium-therapeutics-dftx-and-ideaya-biosciences-idya-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4588","DFTX","VOR","BK4585","XBI","BK4137","BK4581","LABU","XLV","HCSG","BK4007","IDYA","LU0029874061.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659816653","title":"Citi Remains a Buy on Vor Biopharma (VOR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659816653","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659816653?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:55","pubTimestamp":1786636543,"startTime":"0","endTime":"0","summary":"Citi analyst Geoff Meacham maintained a Buy rating on Vor Biopharma today and set a price target of $50.00. Meacham covers the Healthcare sector, f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-remains-a-buy-on-vor-biopharma-vor-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-remains-a-buy-on-vor-biopharma-vor-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOR","LABU","BK4585","BK4581","BK4139","XBI","XLV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659290909","title":"Vor Biopharma is Maintained at Neutral by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2659290909","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659290909?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:15","pubTimestamp":1786551300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VOR/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658302903","title":"Vor Biopharma (VOR) Receives a Hold from Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2658302903","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658302903?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:55","pubTimestamp":1786542932,"startTime":"0","endTime":"0","summary":"In a report released today, Martin Fan from Wedbush maintained a Hold rating on Vor Biopharma, with a price target of $27.00. According to TipRanks...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vor-biopharma-vor-receives-a-hold-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vor-biopharma-vor-receives-a-hold-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658919740","title":"Wedbush Adjusts Price Target on Vor Biopharma to $27 From $18, Keeps Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2658919740","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658919740?lang=en_us&edition=fundamental","pubTime":"2026-08-11 22:58","pubTimestamp":1786460339,"startTime":"0","endTime":"0","summary":"Vor Biopharma (VOR) has an average rating of buy and mean price target of $37.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658166109","title":"Vor Biopharma Shares Drop After Q2 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658166109","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658166109?lang=en_us&edition=fundamental","pubTime":"2026-08-11 22:05","pubTimestamp":1786457133,"startTime":"0","endTime":"0","summary":"Vor Biopharma  shares were down 1.2% in Tuesday trading after the company reported its Q2 results.The company reported a Q2 net loss of $1.16 per diluted share, narrower than a loss of $251.24 a year earlier.Analysts polled by FactSet expected a loss $0.70.As of June 30, the company said it had $466.1 million in cash, cash equivalents and marketable securities, which it expects to fund operations through early 2029 taking into account $48.4 million net proceeds from at-the-market sales during July.Price: 23.13, Change: -0.24, Percent Change: -1.03","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658152299","title":"Vor Biopharma Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658152299","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658152299?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:46","pubTimestamp":1786456004,"startTime":"0","endTime":"0","summary":"Vor Biopharma Inc. reports results for the quarter ended June 30 - Earnings SummaryVor Biopharma Inc.VOR.OQreported a quarterly adjusted loss of $1.16 per share for the quarter ended June 30, higher t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N4481D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658191549","title":"Vor Biopharma Posts Wider-than-Expected Q2 Loss on Increased G&A Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658191549","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658191549?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:42","pubTimestamp":1786455769,"startTime":"0","endTime":"0","summary":"Vor Biopharma posts wider-than-expected Q2 loss on increased G&A costsOverviewUS biotech firm's Q2 net loss widened, missing analyst expectationsR&D expenses dropped sharply yr/yr due to prior licensi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480KQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX","BK4505","BK4139","MREO","ACHV","VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658137915","title":"Vor Biopharma Q2 EPS $(1.16) Misses $(0.70) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658137915","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658137915?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:36","pubTimestamp":1786455385,"startTime":"0","endTime":"0","summary":"Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.70) by 65.71 percent. This is a 99.54 percent increase over losses of $(251.24) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61109624/vor-biopharma-q2-eps-1-16-misses-0-70-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658091513","title":"Earnings Flash (VOR) Vor Biopharma Posts Q2 Net Loss $1.16 a Share, vs. FactSet Est of $0.70 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658091513","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658091513?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:34","pubTimestamp":1786455278,"startTime":"0","endTime":"0","summary":"Price: 23.05, Change: -0.32, Percent Change: -1.39","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658915510","title":"Vor Biopharma Q2 Net Income USD -62.8 Million VS. Ibes Estimate USD -35.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658915510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658915510?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:30","pubTimestamp":1786455000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLX9VS266:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658915593","title":"Press Release: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658915593","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658915593?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:30","pubTimestamp":1786455000,"startTime":"0","endTime":"0","summary":"placebo-controlled Phase 3 registrational trial with an open-label. extension assessing the efficacy and safety of telitacicept in gMG. -- Topline data anticipated in 1H 2027Primary Sjgren's Disease-- UPSTREAM SjD. efficacy and safety of telitacicept in SjDCorporate Updates-- Appointed David Zaccardelli, Pharm.D., former Chief Executive Officer and. President of Verona Pharma, to its Board of Directors. approved telitacicept for the treatment of adult patients with SjD and. -- Results from the Phase 3 TELIGAN trial evaluating telitacicept in IgAN in. China were published in The New England Journal of MedicineSecond Quarter 2026 Financial Results-- Cash Position: Cash, cash equivalents and marketable securities were. $466.1 million as of June 30, 2026, which together with the $48.4 million. net proceeds from at-the-market sales during July 2026, are projected to. -- Research & Development (R&D) Expenses: R&D expenses for the second. quarter of 2026 were $25.9 million, compared to $261.5","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOR","SLE","RA","BK4077","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vorbio.com","stockEarnings":[{"period":"1week","weight":-0.1346},{"period":"1month","weight":-0.2176},{"period":"3month","weight":0.1503},{"period":"6month","weight":0.279},{"period":"1year","weight":-0.4522},{"period":"ytd","weight":0.4159}],"compareEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0069},{"period":"3month","weight":0.0581},{"period":"6month","weight":0.2165},{"period":"1year","weight":0.1722},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.04043},{"month":2,"riseRate":0.6,"avgChangeRate":0.020325},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.093017},{"month":4,"riseRate":0,"avgChangeRate":-0.182481},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.222738},{"month":6,"riseRate":0.5,"avgChangeRate":1.13274},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.011394},{"month":8,"riseRate":0.5,"avgChangeRate":0.011621},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.074609},{"month":10,"riseRate":0.6,"avgChangeRate":-0.046096},{"month":11,"riseRate":0.2,"avgChangeRate":-0.192554},{"month":12,"riseRate":1,"avgChangeRate":0.3146}],"exchange":"NASDAQ","name":"Vor Biopharma Inc.","nameEN":"Vor Biopharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vor Biopharma Inc.(VOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vor Biopharma Inc.(VOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vor Biopharma Inc.,VOR,Vor Biopharma Inc.股票,Vor Biopharma Inc.股票老虎,Vor Biopharma Inc.股票老虎国际,Vor Biopharma Inc.行情,Vor Biopharma Inc.股票行情,Vor Biopharma Inc.股价,Vor Biopharma Inc.股市,Vor Biopharma Inc.股票价格,Vor Biopharma Inc.股票交易,Vor Biopharma Inc.股票购买,Vor Biopharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vor Biopharma Inc.(VOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vor Biopharma Inc.(VOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}